Lilly bolsters leadership team with neuroscience and immunology in mind
Dr Carole Ho joins from Denali Therapeutics and there are promotions for Adrienne Brown and Daniel Skovronsky.
List view / Grid view
Dr Carole Ho joins from Denali Therapeutics and there are promotions for Adrienne Brown and Daniel Skovronsky.
The €2.6 billion manufacturing investment complements the recent US manufacturing expansion for its next potential blockbuster obesity treatment orforglipron.
Novo Nordisk’s “bold” $6.5 billion bid subject to a final verdict by Metsera’s board of directors.
Cultural change inside pharma needed to help attract tech talent and support a deeper adoption of AI in the industry, say recruiters at CPHI Frankfurt 2025.
Winners at the ceremony in Frankfurt also included CNX Therapeutics, NunaBio, Evonik Industries and Corden Pharma.
Speaking at CPHI Frankfurt, Bruno Fabre underlined the importance of companies viewing the technology as a fundamental business capability, rather than “an afterthought”.
Pharma giant plans to harness its “decades of data” and use AI to set a new scientific standard that accelerates pharmaceutical innovation.
Model offers mid market innovators and larger pharma companies tailored processes and scale capacity without compromising compliance.
Approval provides continuity of care into adulthood for patients with neurofibromatosis type 1 (NF1) using Koselugo (selumetinib) to manage symptoms.
Deal to advance potential first-in-class RNA therapeutics focused on genetic neuromuscular diseases such as Duchenne muscular dystrophy.
The new biopharmaceutical production facility represents the CDMO’s largest single investment at its headquarters in Lauphei, Germany.
New findings support use of salbutamol MDI formulation in the next-generation low carbon propellant as a more sustainable option for patients with respiratory disease.
The move will boost its oncology pipeline, adding a potential first-in-class anti-BTN3A monoclonal antibody for acute myeloid leukaemia.
The company will instead focus its attention on advancing candidates for modalities that include biologics and ADCs.
The US FDA approvals make the drug the first IL-23 inhibitor to be licensed for two common skin conditions.